

July 24, 2006

Dainippon Sumitomo Pharma Co., Ltd.
Bristol-Myers K.K.

Partnership Agreements Concerning Anti-Hypertension & Hepatocellular Cancer Drugs Reached

Dainippon Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Kenjiro Miyatake) and Bristol-Myers K.K. (Head Office: Shinjuku, Tokyo; President: Russell J. Bloem) announced today that DSP and BMKK have entered into the following agreements:

1. BMKK has sublicensed to DSP its domestic Japanese development, manufacturing/marketing and marketing rights of “irbesartan” (generic name), an anti-hypertension drug discovered by sanofi-aventis (Head Office: Paris, France); and
2. DSP has granted to BMKK domestic co-marketing rights of “SM-11355” (generic name: miriplatin hydrate), an agent discovered and being developed as a therapy to treat hepatocellular carcinoma by DSP.

Internationally, irbesartan – an angiotensin receptor blocker (ARB) – has been co-developed by sanofi-aventis and Bristol Myers Squibb Company (Head Office: New York State) and was first launched in 1997. Its global sales for 2005 was approximately 892 Million Euros (excluding combination drugs) and it has been highly regarded as one of the top brands of ARBs. Domestically, it has been co-developed by Shionogi & Co., Ltd. and BMKK under coordination by sanofi-aventis K.K. (Head Office: Shinjuku, Tokyo). Currently Phase III trials are underway in Japan. The agreement will enable DSP to co-develop the drug with Shionogi & Co., Ltd., under coordination by sanofi-aventis K.K. and, after obtaining manufacturing and marketing approval, to market it with Shionogi & Co., Ltd. DSP, which currently markets “Amlodin,” a calcium antagonist, expects the addition of “irbesartan” will provide an opportunity to further expand its lineup in the anti-hypertension area.

“SM-11355”, a lipophilic platinum complex, is now under Phase II development in Japan by DSP as an hepatic arterial injection chemotherapy suspended in lipiodol to treat hepatocellular carcinoma. The agreement will enable DSP and BMKK to co-market the drug following DSP’s obtaining manufacturing and marketing approval.

BMKK will sharpen its focus on its 10 key disease areas including cancer, HIV, hepatitis and other diseases through the agreement to co-market the hepatocellular carcinoma drug.

For more information, please contact:

Public Relations,
Dainippon Sumitomo Pharma Co., Ltd.
2-6-8, Dosho-machi, Chuo-ku, Osaka-shi
TEL: 06-6203-1407

Corporate & Business Communications,
Bristol-Myers K.K.
6-5-1, Nishi-Shinjuku, Shinjuku-ku, Tokyo
TEL: 03-5323-8314